Evidence map›Paper›PMID 37236664›Full record

ArticleBMJ open2023

Interactions between Australian cancer physicians and the pharmaceutical industry: a qualitative study.

Adrian M J Pokorny, Lisa A Bero, Peter Fox, Deme J Karikios, Eliza J McEwin, Ray Moynihan, Barbara Mintzes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Adrian M J PokornyFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia apokorny@uni.sydney.edu.au.ORCID 0000-0002-6987-0499
Lisa A BeroFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1893-6651
Peter FoxCentral West Cancer Care Centre, Orange Health Service, Orange, New South Wales, Australia.
Deme J KarikiosDepartment of Medical Oncology, Nepean Hospital, Kingswood, New South Wales, Australia.
Eliza J McEwinFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Ray MoynihanFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Barbara MintzesFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-8671-915X
The University of Sydney · AUBond University · AUNepean Hospital · AUWestern NSW Local Health District · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo understand how and why Australian cancer physicians interact with the pharmaceutical industry.

designQualitative study using semistructured interviews, performed by a medical oncologist. Thematic analysis using a combination of deductive and inductive codes.

settingGiven the evidence on industry influences on clinical practice and the importance to the market of oncology drugs, we sought to better understand cancer physicians' experiences. Practising consultant medical oncologists and clinical haematologists from four Australian states were interviewed over Zoom.

participants16 cancer physicians were interviewed between November 2021 and March 2022, from 37 invited (response rate 43%). Most were medical oncologists (n=12 of 16, 75%) and male (n=9 of 16, 56%). OUTCOME MEASURES: The analysis of all interviews was based on grounded theory. Transcripts were coded and then codes formed into themes with supporting quotes. The themes were then placed into categories, used to describe the broad areas into which the themes could be grouped.

resultsSix themes were identified that fell within two broad categories: cancer physicians'

conclusionsCancer physicians may have difficulty balancing the perceived need to interact with industry in modern cancer care while maintaining distance to minimise conflicts of interest. Further research is needed to assess management strategies in this area.

Indexed as

Drug IndustryMedical OncologyPhysiciansAttitude of Health PersonnelAustraliaConflict of InterestCOVID-19FemaleHumansMaleNeoplasmsPandemicsQualitative ResearchHAEMATOLOGYHealth policyMEDICAL ETHICSONCOLOGY

Identifiers

PMID37236664
PMCPMC10230892
OpenAlexW4378473240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.